ZyVersa Therapeutics, Inc. (ZVSA): Nasdaq/NYSE listing notice — ZyVersa receives Nasdaq notice for non-compliance with minimum MVPHS of $5M

ZyVersa Therapeutics, Inc.

Nasdaq letter dated Sept 1, 2023 for failure to meet minimum Market Value of Publicly Held Shares of $5M.
Company has 180 calendar days, until Feb 28, 2024, to regain compliance by closing MVPHS ≥$5M for 10 consecutive business days.
Failure to regain compliance could lead to delisting; company may consider transfer to Nasdaq Capital Market.
Common stock continues to trade on Nasdaq Global Market under symbol ZVSA with no immediate effect.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C), 5810(c)(3)(D)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(1)(C), 5810(c)(3)(D)

Exact text from the filing

September 1, 2023, ZyVersa Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the Company is not in compliance with the requirement of a minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000 for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(1)(C). Nasdaq calculates MVPHS by subtracting from the total shares of common stock outstanding any shares held by officers, directors or any person who benefic

View on SEC.gov

Browse all listing & compliance notices →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-032103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.